Program
eltrombopag
Also written as “Eltrombopag”, “SB497115” and “Eltrombopag olamine”.
Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Thrombocytopenia · Anemia, Aplastic · Purpura · Hepatitis C, Chronic, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 290 open or running | phase 4since Jan 7, 2010 | Feb 1, 2005 | none ahead |
| Novartis | 182 open or running | phase 4since Oct 4, 2013 | Jul 10, 2006 | Apr 22, 2033phase 2 · NCT07660172 |
| Bristol-Myers Squibb | 10 open or running | phase 1since Jun 20, 2023 | Jun 20, 2023 | none ahead |
| Renata | 11 open or running | phase 2since Jul 6, 2024 | Jul 6, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 35 studies since Feb 1, 2005.
- Sep 29, 2014Phase 1 study in Liver CirrhosisGlaxoSmithKline · NCT02254434 · 26 enrolled · Mexico
- Oct 30, 2014Phase 1 study in Purpura, Thrombocytopenic, IdiopathicGlaxoSmithKline · NCT02281370 · 39 enrolled · United States
- Feb 26, 2015Phase 2 study in Anemia, AplasticNovartis · NCT02404025 · 10 enrolled · Japan
- Nov 4, 2016Phase 2 study in Anemia, AplasticNovartis · NCT02998645 · 54 enrolled · Brazil, Hong Kong, India and more
- Jan 12, 2017Phase 2 study in Anemia, AplasticNovartis · NCT03025698 · 51 enrolled · United States, Hong Kong, Portugal and more
- May 2, 2018Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNovartis · NCT03524612 · 105 enrolled · United States, Austria, Brazil and more
- Oct 23, 2018Phase 2 study in Poor Graft FunctionNovartis · NCT03718533 · 10 enrolled · Spain
- Jun 13, 2019Phase 2 study in Anemia, AplasticNovartis · NCT03988608 · 20 enrolled · China
- Mar 9, 2020Phase 2 study in Anemia, AplasticNovartis · NCT04328727 · 36 enrolled · China, Japan, South Korea and more
- Apr 12, 2020Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNovartis · NCT04346654 · 26 enrolled · Germany
- Mar 4, 2021Phase 2 study in Myelodysplastic SyndromesNovartis · NCT04797000 · 36 enrolled · Japan
- Jun 20, 2023Bristol-Myers Squibb's first study: phase 1 study in Healthy AdultsNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT05924152 · 16 enrolled · United States
- Jul 6, 2024Renata's first study: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNew to RenataRenata · NCT06531018 · 100 planned · Bangladesh
- Jun 15, 2026Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNovartis · NCT07660172 · 36 planned
Ahead
- Apr 22, 2033Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNovartis · NCT07660172
TargetBeta
“Thrombopoietin receptor agonist; Thrombopoietin receptor agonist”ChEMBL 37, by rule
Other programs on MPL
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| romiplostimrule | Amgen | phase 4 | 38 |
| avatrombopagrule | Eisai | phase 4 | 25 |
| hetrombopag olaminerule | Jiangsu HengRui Medicine | phase 3 | 15 |
Studies
All 49 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07660172Purpura, Thrombocytopenic, Idiopathic | 2 | Not yet recruiting | Novartis | Apr 22, 2033 | 36 |
| NCT06531018Purpura, Thrombocytopenic, Idiopathic · Bangladesh | 2 | Recruiting | Renata | Aug 31, 2025 | 100 |
| NCT05924152Healthy Adults · United States | 1 | Completed | Bristol-Myers Squibb | Aug 9, 2023 | 16 |
| NCT04797000Myelodysplastic Syndromes · Japan | 2 | Active, not recruiting | Novartis | Apr 26, 2025 | 36 |
| NCT04346654Purpura, Thrombocytopenic, Idiopathic · Germany | 2 | Completed | Novartis | Sep 22, 2023 | 26 |
| NCT04328727Anemia, Aplastic · China, Japan, South Korea and more | 2 | Completed | Novartis | Jun 10, 2022 | 36 |
| NCT03988608Anemia, Aplastic · China | 2 | Completed | Novartis | Jul 16, 2021 | 20 |
| NCT03718533Poor Graft Function · Spain | 2 | Terminated | Novartis | Nov 3, 2020 | 10 |
| NCT03524612Purpura, Thrombocytopenic, Idiopathic · United States, Austria, Brazil and more | 2 | Completed | Novartis | Oct 22, 2021 | 105 |
| NCT03025698Anemia, Aplastic · United States, Hong Kong, Portugal and more | 2 | Completed | Novartis | Apr 22, 2022 | 51 |
| NCT02998645Anemia, Aplastic · Brazil, Hong Kong, India and more | 2 | Completed | Novartis | Nov 3, 2020 | 54 |
| NCT02404025Anemia, Aplastic · Japan | 2 | Completed | Novartis | Jul 5, 2016 | 10 |
| NCT02281370Purpura, Thrombocytopenic, Idiopathic · United States | 1 | Completed | GlaxoSmithKline | Dec 24, 2014 | 39 |
| NCT02254434Liver Cirrhosis · Mexico | 1 | Completed | GlaxoSmithKline | Sep 8, 2014 | 26 |
| NCT02158936Thrombocytopenia · United States, Argentina, Australia and more | 3 | Terminated | Novartis | Apr 30, 2016 | 356 |
| NCT02148133Anemia, Aplastic · Japan | 2 | Completed | Novartis | Sep 10, 2015 | 21 |
| NCT01957176Thrombocytopenia · Belgium, China, France and more | 4 | Completed | Novartis | Feb 23, 2022 | 22 |
| NCT01890746Leukemia · United States, Australia, Belgium and more | 2 | Completed | Novartis | Mar 13, 2015 | 148 |
| NCT02201290Purpura, Thrombocytopenic, Idiopathic · Russian Federation | 3 | Completed | Novartis | Jul 4, 2017 | 9 |
| NCT01762761Purpura · China | 3 | Completed | Novartis | Jun 5, 2014 | 155 |
| NCT01657552Thrombocytopenia · United States | 1 | Completed | GlaxoSmithKline | Oct 26, 2012 | 56 |
| NCT01636778Hepatitis C, Chronic · Japan | 2 | Completed | GlaxoSmithKline | May 2014 | 45 |
| NCT01520909Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Czech Republic and more | 3 | Completed | GlaxoSmithKline | Jan 2014 | 92 |
| NCT01440374Thrombocytopenia · United States, Argentina, Belgium and more | 2 | Completed | Novartis | Mar 2015 | 162 |
| NCT01147809Thrombocytopenia · United States, Belgium, Canada and more | 2 | Completed | GlaxoSmithKline | Jan 2015 | 130 |
| NCT01098487Purpura · United States, Czech Republic, France and more | 4 | Completed | GlaxoSmithKline | May 2014 | 167 |
| NCT01072162Purpura · United States | 1 | Completed | GlaxoSmithKline | Apr 7, 2010 | 40 |
| NCT01055600Thrombocytopenia · United States | 4 | Withdrawn | GlaxoSmithKline | Jul 2014 | 0 |
| NCT00996216Hepatitis C · United States, Australia, Canada and more | 3 | Completed | GlaxoSmithKline | Feb 2013 | 27 |
| NCT00908037Purpura · United States, Canada, France and more | 2 | Completed | GlaxoSmithKline | Feb 1, 2014 | 82 |
| NCT00903422Myelodysplastic Syndromes · United States, Brazil, Denmark and more | 1 | Completed | GlaxoSmithKline | Jun 26, 2012 | 98 |
| NCT00861601Liver Diseases · Japan | 2 | Completed | GlaxoSmithKline | Aug 2009 | 38 |
| NCT00833378Hepatitis C · United States | 1 | Completed | GlaxoSmithKline | Mar 11, 2009 | 40 |
| NCT00828750Purpura, Thrombocytopenic, Idiopathic · Japan | 3 | Completed | GlaxoSmithKline | Feb 2011 | 19 |
| NCT00688272Purpura · United Kingdom | 1 | Completed | GlaxoSmithKline | Sep 25, 2008 | 36 |
| NCT00678587Non-alcoholic Fatty Liver Disease · United States, Argentina, Belgium and more | 3 | Terminated | GlaxoSmithKline | Oct 2009 | 292 |
| NCT00540423Purpura, Thrombocytopenic, Idiopathic · Japan | 3 | Completed | GlaxoSmithKline | Dec 2008 | 23 |
| NCT00529568Hepatitis C, Chronic · United States, Australia, Belgium and more | 3 | Completed | GlaxoSmithKline | Aug 2011 | 759 |
| NCT00516321Hepatitis C, Chronic · United States, Australia, Belgium and more | 3 | Completed | GlaxoSmithKline | Apr 2011 | 687 |
| NCT00487968Purpura, Thrombocytopenic, Idiopathic · United States | 1 | Completed | GlaxoSmithKline | 12 | |
| NCT00442871Purpura · United States | 1 | Completed | GlaxoSmithKline | Jan 3, 2008 | 29 |
| NCT00424177Purpura · Germany, Russian Federation | 2 | Completed | GlaxoSmithKline | Aug 2008 | 66 |
| NCT00370331Purpura · United States, Austria, Canada and more | 3 | Completed | GlaxoSmithKline | Jul 2008 | 197 |
| NCT00359463Purpura · United States, Australia, New Zealand | 1 | Completed | GlaxoSmithKline | Mar 7, 2007 | 33 |
| NCT00358540Thrombocytopenia · United States | 1 | Completed | GlaxoSmithKline | Oct 22, 2010 | 18 |
| NCT00351468Purpura · United States, Australia, Austria and more | 3 | Completed | Novartis | Jul 2015 | 302 |
| NCT00110799Hepatitis C, Chronic · United States, France, Germany and more | 2 | Completed | GlaxoSmithKline | Oct 2006 | 75 |
| NCT00102739Purpura · Germany, Greece, Hong Kong and more | 2 | Completed | GlaxoSmithKline | Jan 2007 | 99 |
| NCT00102726Thrombocytopenia · United States, Argentina, Austria and more | 2 | Completed | GlaxoSmithKline | Feb 2007 | 183 |
How it is read
Names in the registry
- “Eltrombopag”, 19 entries
- “eltrombopag”, 15 entries
- “SB497115”, 3 entries
- “Eltrombopag olamine”, 2 entries
- “Eltrombopag 25 MG”, 1 entry
Conditions, from the studies’ own filings
- Purpura, Thrombocytopenic, Idiopathic, 15 studies
- Thrombocytopenia, 8 studies
- Anemia, Aplastic, 6 studies
- Purpura, 5 studies
- Hepatitis C, Chronic, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.